搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
22 小时
AbbVie和Richter扩大中枢神经系统合作伙伴关系,达成新协议
伊利诺伊州北芝加哥 - 艾伯维公司(纽约证券交易所代码:ABBV)和Gedeon Richter Plc.宣布达成协议,共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上,该合作关系已经产生了中枢神经系统疗法,包括cariprazine(VRAYLAR® / REAGILA®)和研究中的药物ABBV-932。
7 分钟
If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. It is set to report its Q3 ...
FierceBiotech
2 小时
AbbVie makes Richter richer, paying $25M to form discovery pact with Vraylar originator
AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...
Emirates247
1 小时
CRISP Program, a new step by AbbVie to foster scientific expertise in the Middle East and ...
AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...
bovnews
1 小时
Uncover the Reason: Why AbbVie Inc (ABBV) Stock Is Trading 39.60% Above Its 52-Week Low?
On Thursday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $189.65 which represents a slight increase of $1.77 or 0.94% from the prior close of $187.88. The stock opened at $188.43 ...
5 小时
AbbVie and Richter partner for neuropsychiatric treatments
Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...
4 小时
Argent Capital Management LLC Has $761,000 Stock Position in AbbVie Inc. (NYSE:ABBV)
Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...
Zacks.com on MSN
2 天
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
1 天
AbbVie: Expect A Beat-And-Raise Q3 2024
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
18 小时
AbbVie, Gedeon Richter collaborate for discovery, development of novel targets
AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...
3 天
AbbVie: Strong Dividends But Humira Disappoints
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
2 天
AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈